• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Can Real-World Evidence Help Restore Decades of Health Inequalities by Informing Health Care Decision-Making? Certainly, and Here is How.

作者信息

Sarri Grammati

机构信息

Head of RWAA External Research Partnerships/Senior Research Principal, Cytel Inc., London, United Kingdom.

出版信息

Front Pharmacol. 2022 Jun 14;13:905820. doi: 10.3389/fphar.2022.905820. eCollection 2022.

DOI:10.3389/fphar.2022.905820
PMID:35784688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9241066/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37f2/9241066/6e470ee617f3/fphar-13-905820-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37f2/9241066/6e470ee617f3/fphar-13-905820-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37f2/9241066/6e470ee617f3/fphar-13-905820-g001.jpg

相似文献

1
Can Real-World Evidence Help Restore Decades of Health Inequalities by Informing Health Care Decision-Making? Certainly, and Here is How.真实世界证据能否通过为医疗保健决策提供信息来消除数十年的健康不平等？答案是肯定的，方法如下。
Front Pharmacol. 2022 Jun 14;13:905820. doi: 10.3389/fphar.2022.905820. eCollection 2022.
2
Payer perceptions of the use of real-world evidence in oncology-based decision making.支付者对基于肿瘤学的决策中使用真实世界证据的看法。
J Manag Care Spec Pharm. 2021 Aug;27(8):1096-1105. doi: 10.18553/jmcp.2021.27.8.1096.
3
A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.用于评估真实世界证据为不同利益相关者创造的价值的综合框架：以协作登记网络为例。
Ther Innov Regul Sci. 2024 Nov;58(6):1042-1052. doi: 10.1007/s43441-024-00680-z. Epub 2024 Jul 25.
4
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.提高透明度以建立对假设检验的真实世界二次数据研究的信任——原因、内容和方法：来自真实世界证据透明度倡议的建议和路线图。
Value Health. 2020 Sep;23(9):1128-1136. doi: 10.1016/j.jval.2020.04.002.
5
Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.在线工具合成比较有效性研究的真实世界证据，以加强处方决策。
J Manag Care Spec Pharm. 2021 Jan;27(1):95-104. doi: 10.18553/jmcp.2021.27.1.095.
6
Real-world evidence for regulatory decision-making: updated guidance from around the world.用于监管决策的真实世界证据：来自世界各地的最新指南。
Front Med (Lausanne). 2023 Oct 30;10:1236462. doi: 10.3389/fmed.2023.1236462. eCollection 2023.
7
Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.亚洲用于报销决策的卫生技术评估的真实世界数据：现状与未来方向。
Int J Technol Assess Health Care. 2020 Oct;36(5):474-480. doi: 10.1017/S0266462320000628. Epub 2020 Sep 15.
8
Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact.衡量真实世界证据的有效性，以确保产生适当影响。
Value Health. 2021 Sep;24(9):1241-1244. doi: 10.1016/j.jval.2021.03.020. Epub 2021 Jun 26.
9
The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies.真实世界证据在药品获益-风险评估、沟通和评价中的应用：案例研究。
Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1532-1539. doi: 10.1002/pds.5167. Epub 2020 Nov 17.
10
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.提高透明度以增强对用于假设检验的真实世界二次数据研究的信任——为何、是什么以及如何做：来自真实世界证据透明度倡议的建议和路线图
Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1504-1513. doi: 10.1002/pds.5079. Epub 2020 Sep 13.

引用本文的文献

1
Drug outcomes research and policies - trends and challenges.药物疗效研究与政策——趋势与挑战
Front Pharmacol. 2024 Aug 26;15:1476849. doi: 10.3389/fphar.2024.1476849. eCollection 2024.
2
The potential role of real-world evidence in Centers for Medicare & Medicaid Services' future price negotiations: Recommendations for a robust framework.真实世界证据在医疗保险和医疗补助服务中心未来价格谈判中的潜在作用：关于一个稳健框架的建议
J Manag Care Spec Pharm. 2024 Jun;30(6):604-607. doi: 10.18553/jmcp.2024.30.6.604.
3
Opportunity and accessibility: an environmental scan of publicly available data repositories to address disparities in healthcare decision-making.

本文引用的文献

1
Best practices in the real-world data life cycle.真实世界数据生命周期中的最佳实践。
PLOS Digit Health. 2022 Jan 18;1(1):e0000003. doi: 10.1371/journal.pdig.0000003. eCollection 2022 Jan.
2
A systematic review of inequalities in the uptake of, adherence to, and effectiveness of behavioral weight management interventions in adults.一项系统评价成人在接受、坚持和行为体重管理干预有效性方面的不平等。
Obes Rev. 2022 Jun;23(6):e13438. doi: 10.1111/obr.13438. Epub 2022 Mar 3.
3
Advancing digital health applications: priorities for innovation in real-world evidence generation.
机遇与可及性：公共可用数据存储库的环境扫描，以解决医疗决策中的差异问题。
Int J Equity Health. 2024 May 8;23(1):93. doi: 10.1186/s12939-024-02187-3.
4
What to Expect in 2024: Important Health Economics and Outcomes Research (HEOR) Trends.2024年展望：重要的卫生经济与结果研究（HEOR）趋势
Clinicoecon Outcomes Res. 2023 Dec 21;15:799-809. doi: 10.2147/CEOR.S453171. eCollection 2023.
5
Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements.重构卫生技术评估中的价值难题：一项务实性综述，以确定哪些建模方法能够涵盖额外的价值要素。
Front Pharmacol. 2023 Jul 13;14:1197259. doi: 10.3389/fphar.2023.1197259. eCollection 2023.
推进数字健康应用：真实世界证据生成创新的优先事项。
Lancet Digit Health. 2022 Mar;4(3):e200-e206. doi: 10.1016/S2589-7500(21)00292-2.
4
Use of a community advisory board to build equitable algorithms for participation in clinical trials: a protocol paper for HoPeNET.利用社区咨询委员会为临床试验参与制定公平算法：HoPeNET 的方案文件。
BMJ Health Care Inform. 2022 Feb;29(1). doi: 10.1136/bmjhci-2021-100453.
5
ISPE-Endorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVID-19: Opportunities and Trade-Offs.ISPE 认可的使用电子健康记录进行 COVID-19 比较有效性研究的指南：机会与权衡。
Clin Pharmacol Ther. 2022 Nov;112(5):990-999. doi: 10.1002/cpt.2560. Epub 2022 Mar 11.
6
Using Economic Evaluation to Hasten Health Equity.利用经济评估促进健康公平。
Health Equity. 2021 Sep 15;5(1):627-632. doi: 10.1089/heq.2021.0010. eCollection 2021.
7
Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value.欧盟药品监管中的真实世界证据：促进使用与确立价值
Clin Pharmacol Ther. 2022 Jan;111(1):21-23. doi: 10.1002/cpt.2479. Epub 2021 Nov 19.
8
Trends in Differences in Health Status and Health Care Access and Affordability by Race and Ethnicity in the United States, 1999-2018.1999-2018 年美国种族和民族之间健康状况和医疗保健可及性及可负担性差异的趋势。
JAMA. 2021 Aug 17;326(7):637-648. doi: 10.1001/jama.2021.9907.
9
The use of nonrandomized evidence to estimate treatment effects in health technology assessment.使用非随机证据来评估卫生技术评估中的治疗效果。
J Comp Eff Res. 2021 Oct;10(14):1035-1043. doi: 10.2217/cer-2021-0108. Epub 2021 Jul 19.
10
Reporting of Participant Race, Sex, and Socioeconomic Status in Randomized Clinical Trials in General Medical Journals, 2015 vs 2019.2015 年与 2019 年普通医学期刊随机临床试验中报告参与者种族、性别和社会经济地位的情况。
JAMA Netw Open. 2021 May 3;4(5):e2111516. doi: 10.1001/jamanetworkopen.2021.11516.